Iroda Pulatovna Sharipova

Iroda Pulatovna Sharipova

Auto-generated profile, based on publicly available information

Iroda Pulatovna Sharipova

Research Institute of Virology, 7a, Yangi shahar, Yunus Abad, Tashkent, 100194, Uzbekistan

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
ISIroda Pulatovna Sharipova
Iroda Pulatovna Sharipova
EMErkin Isakovich Musabaev
Erkin Isakovich Musabaev
SSShakhlo Sobirovna Sadirova
Shakhlo Sobirovna Sadirova
DSDildora Tolibjonovna Suyarkulova
Dildora Tolibjonovna Suyarkulova
STShavkat Ekrinovich Tashev
Shavkat Ekrinovich Tashev
HKHyunwon Kim
Hyunwon Kim
Sharipova IP, et al. J Gynecol Oncol. 2024 Jun;36:e7. https://doi.org/10.3802/jgo.2025.36.e7

16 December 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
MOMalokhat Palvannazirovna Oltieva
Malokhat Palvannazirovna Oltieva
DADilfuza Abdullaevna Alieva
Dilfuza Abdullaevna Alieva
SASitorabonu Bahodir Kizi Abdusattorova
Sitorabonu Bahodir Kizi Abdusattorova
ISIroda Pulatovna Sharipova
Iroda Pulatovna Sharipova
JJJasur Ravshanovich Juraev
Jasur Ravshanovich Juraev
UMUlugbek Khudayberdievich Mirzaev
Ulugbek Khudayberdievich Mirzaev
Cervical cancer imposes a substantial public health burden in Uzbekistan, yet comprehensive HPV epidemiological data are lacking. This study characterized high-risk HPV prevalence, genotype distribution, risk factors, and screening coverage in three key regions. We analyzed data from 44,497 women aged ≥ 20 years attending gynecological services in Tashkent, Andijan, and Samarkand (2021–2023). Liquid-based cytology and HPV DNA testing for 12 high-risk genotypes were performed. Sociodemographic, reproductive, behavioral, and clinical variables were collected via standardized questionnaires and examination. Multivariable logistic regression identified associated factors of high-risk HPV infection. High-risk HPV was detected in 3,779 women (8.5%), with regional prevalence of 9.2% in Andijan, 8.8% in Tashkent, and 6.5% in Samarkand. Mixed genotype infections comprised 52.8% of cases; HPV-16/18 accounted for 41.1%. Among HPV-positive women undergoing cytology (n = 2,275), 64.1% had negative findings, 14.7% LSIL, 8.4% ASC-US, 6.9% HSIL, 5.1% ASC-H, 0.5% atypical glandular cells, and 0.3% carcinoma. Independent predictors of HPV infection included younger age, single marital status, lower parity, abortion history, and hormonal contraception (all p < 0.05). Foamy vaginal discharge was a significant clinical predictor (adjusted OR 1.53; p < 0.01). Uzbekistan exhibits an intermediate high-risk HPV burden, dominated by vaccine-preventable genotypes, and low screening coverage. Targeted outreach to identified high-risk groups—by age, reproductive history, and clinical features—will optimize resource allocation. These data support accelerated progress toward WHO elimination targets in Uzbekistan. The online version contains supplementary material available at 10.1186/s12879-025-12096-7.